BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts

References

• Penserga E T, Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene 2007; 26: 11–20
   PubMed Web of Science ®Google Scholar
• Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566
   PubMed Web of Science ®Google Scholar
• Oehler V G, Gooley T, Snyder D S, Johnston L, Lin A, Cummings C C, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109: 1782–1789
   PubMed Web of Science ®Google Scholar
• Druker B J, Sawyers C L, Kantarjian H, Resta D J, Reese S F, Ford J M, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042
   PubMed Web of Science ®Google Scholar
• Hughes T P, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley M L, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432
   PubMed Web of Science ®Google Scholar
• Bhatia R, Holtz M, Niu N, Gray R, Snyder D S, Sawyers C L, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701–4707
   PubMed Web of Science ®Google Scholar
• Wolff N C, Richardson J A, Egorin M, Ilaria R L, Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003; 101: 5010–5013
   PubMed Web of Science ®Google Scholar
• Neering S J, Bushnell T, Sozer S, Ashton J, Rossi R M, Wang P Y, et al. Leukemia stem cells in a genetically defined murine model of blast crisis CML. Blood 2007; 110: 2578–2585
   PubMed Web of Science ®Google Scholar
• Huang Q, Wu Y, Snyder D S, Chang K L, Slovak M L, Gaal K K, et al. Clinical and pathologic analysis of 16 cases of relapsed chronic myeloid leukemia after stem cell transplantation. Am J Clin Pathol 2007; 128: 565–570
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin A S, La Rosee P, Muller M C, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196
   PubMed Web of Science ®Google Scholar
• Willis S, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, et al. High sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128–2137
   PubMed Web of Science ®Google Scholar
• Jiang X, Saw K M, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99: 680–693
   PubMed Web of Science ®Google Scholar
• Chu S, Xu H, Shah N P, Snyder D S, Forman S J, Sawyers C L, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093–2098
   PubMed Web of Science ®Google Scholar
• Wendel H G, de Stanchina E, Cepero E, Ray S, Emig M, Fridman J S, et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci USA 2006; 103: 7444–7449
   PubMed Web of Science ®Google Scholar
• Nowicki M O, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104: 3746–3753
   PubMed Web of Science ®Google Scholar
• Koptyra M, Falinski R, Nowicki M O, Stoklosa T, Majsterek I, Nieborowska-Skorska M, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319–327
   PubMed Web of Science ®Google Scholar
• Canitrot Y, Falinski R, Louat T, Laurent G, Cazaux C, Hoffmann J S, et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 2003; 102: 2632–2637
   PubMed Web of Science ®Google Scholar
• Slupianek A, Nowicki M O, Koptyra M, Skorski T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair (Amst) 2006; 5: 243–250
   PubMed Web of Science ®Google Scholar
• Slupphaug G, Kavli B, Krokan H E. The interacting pathways for prevention and repair of oxidative DNA damage. Mutat Res 2003; 531: 231–251
   PubMed Web of Science ®Google Scholar
• Canitrot Y, Lautier D, Laurent G, Frechet M, Ahmed A, Turhan A G, et al. Mutator phenotype of BCR – ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase β. Oncogene 1999; 18: 2676–2680
   PubMed Web of Science ®Google Scholar
• Brazma D, Grace C, Howard J, Melo J V, Holyoke T, Apperley J F, et al. Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. Genes Chromosomes Cancer 2007; 46: 1039–1050
   PubMed Web of Science ®Google Scholar
• Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A, et al. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle 2006; 5: 994–1000
   PubMed Web of Science ®Google Scholar
• Richardson C, Stark J M, Ommundsen M, Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 2004; 23: 546–553
   PubMedGoogle Scholar
• Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki M O, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8: 795–806
   PubMed Web of Science ®Google Scholar
• Marley S B, Gordon M Y. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. Clin Sci (Lond) 2005; 109: 13–25
   PubMed Web of Science ®Google Scholar
• Jamieson C H, Ailles L E, Dylla S J, Muijtjens M, Jones C, Zehnder J L, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657–667
   PubMed Web of Science ®Google Scholar
• Copland M, Hamilton A, Elrick L J, Baird J W, Allan E K, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 2006; 107: 4532–4539
   PubMed Web of Science ®Google Scholar
• Elrick L J, Jorgensen H G, Mountford J C, Holyoake T L. Punish the parent not the progeny. Blood 2005; 105: 1862–1866
   PubMed Web of Science ®Google Scholar
• Barnes D J, Melo J V. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006; 5: 2862–2866
   PubMed Web of Science ®Google Scholar
• Barnes D J, Palaiologou D, Panousopoulou E, Schultheis B, Yong A S, Wong A, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005; 65: 8912–8919
   PubMed Web of Science ®Google Scholar
• Petzer A L, Eaves C J, Barnett M J, Eaves A C. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 1997; 90: 64–69
   PubMed Web of Science ®Google Scholar
• Radich J P, Olavarria E, Apperley J F. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 2004; 18: 685–702
   PubMed Web of Science ®Google Scholar
• Goldman J, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?. Leuk Lymphoma 2006; 47: 1–7
   PubMed Web of Science ®Google Scholar
• Jorgensen H G, Holyoake T L. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 2007; 35(Pt 5)1347–1351
   PubMed Web of Science ®Google Scholar